May 15, 2019 / 11:20PM GMT
Bassil I. Dahiyat - Xencor, Inc. - Co-Founder, CEO, President & Director
It's a pleasure to be here at the Bank of America conference in Las Vegas. I'm Bassil Dahiyat, CEO of Xencor. We're a monoclonal antibody engineering company.
This is our safe harbor slide. You can, of course, always check our filings with the SEC, the 10-Qs and 10-Ks.
We are a protein engineering company and what we focused on is engineering monoclonal antibodies to make them better therapeutics, essentially engineering their immunological properties and their stability and their structures to make better drugs.
We have built really a large intellectual property base around specifically engineering that bottom half of antibodies, it's shown in blue on that diagram on your right. That's called the Fc domain, and that's a part of the antibody that controls many of these features.
We've built a large toolkit that lets us create different kinds of antibody drugs with different advantages and use that to build both a large internal pipeline as well as a number of partnerships.
Our
Xencor Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers